



Cynghrair Niwrolegol Cymru
Wales Neurological Alliance



Cynulliad **National**
Cenedlaethol **Assembly for**
Cymru **Wales**

Cross-Party Group for Neurosciences
Grŵp Traws-bleidiol Niwrowyddonol

Minutes 4th October 1pm – 3pm

Name	Organisation/Constituency or Region
Mark Isherwood AM (Chair)	
Elaine Kember	Parkinsons
Les Durrant	Parkinsons
Therese Durrant	Parkinsons
Dawn McGuinness	Parkinsons (facilitator/ scribe)
Peter Carr	Executive Director of Therapies and Health Science, Aneurin Bevan UHB
Moira Gleed	Dystonia Society
+1	Dystonia Society
+1	Dystonia Society
Jane Johnson Cree	NeuroTherapy Centre
Jacky Hughes	NeuroTherapy Centre
Karen Shepherd	Patient/ Carer rep North Wales Neurosciences Board
Sian Dorward	MS Society
Cat Shorney Jones	MS Society (facilitator/ scribe)
Emily Owen	MS Society (facilitator/ scribe)
Christine Roberts	Biogen
Duncan Reeves	Biogen
Chris Rowland	Ipsen
Ana Palazon	Parkinsons (facilitator/ scribe)
Ann Sivapatham	Epilepsy Action Cymru facilitator/ scribe)
Jane Paterson	Epilepsy Action Cymru
+1	Epilepsy Action Cymru
+1	Epilepsy Action Cymru
+1	Epilepsy Action Cymru
Kevin Thomas	MNDA
Matt O Grady	Stroke Association
+1	Stroke Association
Eluned Plack	
Nicola Savage	Clinical Specialist Physiotherapist – Neurology, BCUHB
Annette Morris	Director of Neurosciences, BCUHB
Laura Courtney	Consultant (facilitator/ scribe)

Apologies

Llyr Gruffydd AM	North Wales
Kate Langwine Cooke	MS Society
Malley Foulds	MS Society

Welcome and Introduction:

Mark Isherwood AM, Chair of the Cross Party Group on Neurological Conditions introduced the session reminding us of the terms of reference for the including:

- To examine the progress made on implementing the plan across each of the local health boards.
- Whether Wales is on course to achieve the outcomes and performance measures, as set out in each of the chapters of the Delivery Plan, by 2020.
- Whether patients across Wales can access the care required (for example timely diagnosis, access to diagnostics and treatments, palliative and end of life care) in an appropriate setting and in a timely manner
- The level of collaborative working across sectors, especially between the NHS and third sector, to ensure patients receive effective person - centred care from multi-disciplinary teams.
- Whether the current level of funding for neurological services is appropriate, used effectively and provides value for money.

Evidence has so far been submitted to this inquiry by a wide range of stakeholders, including:

- Individuals living with neurological conditions;
- Charities representing people affected by neurological conditions;
- Royal Colleges;
- The Wales Neurological Alliance; and
- The Neurological Conditions Implementation Group.

The purpose of this oral evidence session is to capture the views and experiences of a range of stakeholders about the implementation and impact of the Neurological Conditions Delivery Plan. It will also provide an opportunity to discuss practical solutions for future action.

Table discussions:

Attendees were then asked to consider the following questions at each table.

Question 1: Do you feel the Neurological Conditions Delivery Plan has delivered enough change for people with neurological conditions in Wales? Can you give examples to illustrate your answer?

Question 2: In what ways do you think the Neurological Conditions Delivery Plan has been most successful? Can you give any examples?

Question 3: In what ways do you think the Neurological Conditions Delivery Plan has been least successful? Can you give any examples?

Question 4: Do you have any suggestions for future action which could be taken to improve treatments, services and support for people with neurological conditions in Wales?

Question 5: Do you have any comments on the current level of funding for neurological services in Wales? What are your views on whether funding for neurological services is used effectively and provides value for money?

Question 6: Do you have any comments on the way in which the NHS works together with other organisations, like charities, in providing person centred care to people with neurological conditions?

Closing remarks

Mark Isherwood AM thanked everyone for coming and reminded people that a further evidence session will be held in November with the final report due January 2020.